Gilead Sciences invests $11B to expand pharmaceutical manufacturing and R&D facilities in the United States 

Gilead Sciences has announced plans to expand its manufacturing and research capabilities across the United States. The company, which develops and produces medicines, is investing $11 billion into capital and operational projects, creating around 800 new direct jobs and supporting more than 2,200 indirect jobs by 2028. 

The investment will support the construction of three new facilities and upgrades to three existing sites, focused on boosting U.S. manufacturing and research and development capacity. Of the total investment, $4 billion will be allocated to capital projects such as laboratories and equipment, $5 billion will fund technology, operations, and R&D activities, and $2 billion will support digital and advanced engineering efforts. These developments are part of Gilead’s broader plan to invest $32 billion in U.S. manufacturing and R&D through 2030, which is projected to generate $43 billion in value to the U.S. economy over five years. 

Investing in American manufacturing in 2025 

This map shows where manufacturers are choosing to invest their resources, whether they are building new production facilities or expanding existing plants.